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Abstract
Background: Notwithstanding increasing knowledge of titanium dioxide nanoparticles (TiO2 NPs) passing through
biological barriers, their biodistribution to the central nervous system (CNS) and potential effects on blood-brain
barrier (BBB) physiology remain poorly characterized.
Methods: Here, we report time-related responses from single-dose intravenous (IV) administration of 1 mg/kg TiO2
NPs to rats, with particular emphasis on titanium (Ti) quantification in the brain. Ti content in tissues was analyzed
using inductively coupled plasma mass spectrometry. Integrity and functionality of the BBB as well as brain
inflammation were characterized using a panel of methods including RT-PCR, immuno-histo chemistry and
transporter activity evaluation.
Results: Biokinetic analysis revealed Ti biopersistence in liver, lungs and spleen up to one year after TiO2 NPs
administration. A significant increase of Ti in the brain was observed at early end points followed by a subsequent
decrease. In-depth analysis of Ti in the total brain demonstrated quantitative Ti uptake and clearance by
brain microvasculature endothelial cells (BECs) with minimal translocation in the brain parenchyma. The
presence of Ti in the BECs did not affect BBB integrity, despite rapid reversible modulation of breast cancer
resistance protein activity. Ti biopersistence in organs such as liver was associated with significant increases
of tight junction proteins (claudin-5 and occludin), interleukin 1β (IL-1β), chemokine ligand 1 (CXCL1) and γ
inducible protein-10 (IP-10/CXCL10) in BECs and also increased levels of IL-1β in brain parenchyma despite
lack of evidence of Ti in the brain. These findings mentioned suggest potential effect of Ti present at a
distance from the brain possibly via mediators transported by blood. Exposure of an in vitro BBB model to
sera from TiO2 NPs-treated animals confirmed the tightness of the BBB and inflammatory responses.
Conclusion: Overall, these findings suggest the clearance of TiO2 NPs at the BBB with persistent brain
inflammation and underscore the role of Ti biopersistence in organs that can exert indirect effects on the
CNS dependent on circulating factors.
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Background
Titanium dioxide (TiO2) nanoparticles (NPs) are the sec-
ond most frequently used NPs in industry worldwide
(http://www.nanotechproject.org). TiO2 is widely used as a
white pigment in paint, ink, plastic, and paper and as food
additive, while the nanosized TiO2 is also used for its
photocatalytic activity in self-cleaning materials and for its
UV absorption capacity in sunscreen cosmetics [1]. TiO2 is
also used in the composition of dental prosthesis and im-
plant biomaterials. Because of these multiple applications,
TiO2 is massively produced and as nano-sized particles is
found in variable proportions in daily life products. For ex-
ample, for food grade TiO2 (E171) fraction of particles
under 100 nm, thus corresponding to the strict definition
of NPs was estimated at 36 % by Weir et al. and 5–10 %
reported by Peters et al. [2, 3].
Recent toxicological and pharmacological research on
rodents has shown that TiO2 NPs may translocate across
physiological barriers such as respiratory, intestinal and
vascular epithelium and therefore reach various organs
and tissues including the brain [4–6]. The brain is well
protected by the blood brain barrier (BBB), which con-
tains cells of several types: brain endothelial cells (BECs),
astrocytes, and pericytes [7–11]. These cells communi-
cate closely to guarantee a physical and functional bar-
rier between the blood and the central nervous system
(CNS): tight junctions connecting endothelial cells and
many transporters including two major ATP-driven drug
efflux pumps, the P-glycoprotein (P-gp) and breast can-
cer resistant protein (BCRP) [12–14]. This neurovascular
unit regulates distribution of xenobiotics to the brain.
Fabian et al. reported a lack of translocation of 20 nm
TiO2 NPs to the brain parenchyma 24 h after intraven-
ous (IV) injection of a dose of 5 mg/kg to rats [15].
These findings are further supported by other studies
results in which lack of brain distribution was noticed
6 h following IV administration of 0.95 mg/kg of
Degussa P25 TiO2 NPs to rats [16] and 24 h after
administration of a 10 mg/kg dose of rutile TiO2 NPs to
mice [17]. However, Geraets et al. showed the presence
of TiO2 NPs of different sizes and crystalline forms 24 h
after a 5 mg/kg IV dose in the brain of rats [18]. While
brain translocation of TiO2 NPs after IV administration
remains contradictory, oral and pulmonary exposure in
rodents has shown distribution of TiO2 NPs to the CNS
[18, 19]. Disturbance of neurotransmitters and enzymes,
oxidative stress and inflammatory response have been
described as neurotoxic effects after nasal instillation,
intraperitoneal injection, oral administration or prenatal
exposure [20–25]. These findings raised the question of
the entry of TiO2 NPs into the brain and of their inter-
actions with the BBB.
Our previous data using an in vitro BBB model [26]
show that P25 TiO2 NPs (21.5 nm, 75 − 25 % anatase/
rutile) can accumulate in BECs, with very low and
limited translocation in the glial cells, hinting at the
“physical barrier” role of the BEC epithelium [27]. Over-
all, these contradictory in vitro and in vivo findings show
that additional investigations are needed to ascertain in
vivo brain translocation of TiO2 NPs, interactions
between TiO2 NPs and the BBB, and potential adverse
effects in the brain. These are the main subjects of the
present study.
We used well-characterized anatase/rutile TiO2 NPs
(P25 aeroxide Degussa) to evaluate in vivo biodistribu-
tion of TiO2 NPs, with particular emphasis on in vivo
interactions with the BBB. We evaluated the biokinetics
of TiO2 NPs from 5 min up to one year after IV admin-
istration to adult Fischer rats at a dose of 1 mg/kg. This
mode of administration and concentration was chosen
for comparison to the contradictory literature. Moreover,
IV allows clarify the potential brain translocation under
conditions of 100 % systemic bioavailability without im-
pact of NPs transport across other biological barrier that
could impact NPs. In addition, the potential effects on
BBB physiology and subsequent induction of neuroin-
flammation markers were analyzed.
Results and discussions
Characterization of titanium dioxide nanoparticles
Morphology and size of TiO2 NPs in stock suspensions
were determined by Transmission Electron Microscopy
(TEM). The mean diameter of individual particles was
found to be 21.5 ± 7.2 nm (400 counts) (Fig. 1a). Scan-
ning Electron Microscopy (SEM) confirmed spherical
morphology of particles and Energy Dispersive X-ray
(EDX) analysis on the same images confirmed purity of
the product (i.e. only Ti and O are detected indicating
the absence of other metal contamination greater than
1 %) (Data not shown). Analysis by X-ray diffraction
confirmed the presence of a mixture of 75 % anatase
and 25 % rutile crystal phases (Data not shown). The
specific surface area, 51 m2/g, was measured by
Brunauer–Emmett–Teller (BET) method and corre-
sponds to 30 nm grain diameter.
Dynamic light scattering (DLS) measurements shows
that NPs agglomerate in water and to a larger extent in
saline buffer with hydrodynamic diameters of 163.5 ±
12.6 and 520.9 ± 41.7 nm, respectively (Fig. 1b). Those
measurements highlight the important tendency of TiO2
NPs to aggregate/agglomerate as soon as they are in sus-
pension. We choose not to apply other dispersion proto-
col for in vivo experiments as they usually necessitate
modifying NPs surface. In addition, the size distribution
we obtained is comparable to the one in Fabian, Xie and
Geraets’s study [15, 17, 18] which would ease data con-
frontation. Indeed, it is worth noticing that even agglom-
erated in suspension, NPs form presents a greater
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reactive surface area that may promote adverse effect
compare with the same material particles in micro
size scale.
Biodistribution and accumulation studies of titanium
dioxide nanoparticles
Ti burdens in organs and tissues after IV administration
are shown in Fig. 2. In a previous work, we fully com-
pared four commonly used mineralization methods for
TiO2 NPs and established that one of them involving
nitric and hydrofluoric acids, combined to the inductively
coupled plasma mass spectrometry (ICP-MS) method
allows Ti quantification for NPs in biological samples with
limit of quantification (LOQ) from 4.7 to 33.1 ng/g
depending on the tissue sample mass available. This
method was validated for linearity, repeatability and accur-
acy. Matrix effects and recoveries were checked and quan-
tification limit was determined, sine qua none conditions
for providing valuable data (Devoy et al., 2015 accepted
paper). Ti burdens in liver, spleen and lungs of the treated
group were significantly higher than those of the control
group from 30 min to 356 days (P < 0.001). The Ti level
was higher in the liver than in spleen and lungs. Assays
performed one year after TiO2 NPs administration to rats
indicated that Ti burden remained high, suggesting long-
term biopersistence and no major elimination from
the liver. Indeed, approximately 33 % of the Ti bur-
den at early time points (less than 24 h) remain in
the liver one year after IV administration. The Ti bur-
den in kidneys of the treated group was significantly
higher from 30 min to 24 h, and then decreased sig-
nificantly after 7 days after IV administration. Signifi-
cant levels of Ti were never found in blood (plasma
or blood cells) of the treated group, even at early end
point (i.e. 5 min).
Our findings confirm previous studies showing that
the liver, spleen and lungs appear to be the major organs
of accumulation of TiO2 NPs after IV administration
[15–18, 28] in rodents. We estimate that we recover ap-
proximately 44 % of the administered dose in the liver,
10 % in lungs and 2 % in spleen 6 h after IV administra-
tion. As reported previously, the clearance of TiO2 NPs
from the blood circulation is rapid, so Ti was never de-
tected in plasma or blood cells [15, 28]. The limit of
quantification of the ICP-MS method used is about
15 ng/ml for plasma and about 14 ng/g for blood cells.
Fig. 1 Characterization of TiO2 NPs. a Representative TEM image of the TiO2 NPs (magnification 40.000 x) and size distribution histogram. More
than 400 NPs were measured randomly on several micrographs. The average diameter was 21.5 nm and the standard deviation 7.2. b Size distribution
by intensity obtained by DLS for TiO2 NPs suspended in water (grey) or in saline buffer (black). Vigorous vortexing was the only treatment of the
suspensions and measurement conditions were optimized resulting in a fixed lens position at 4.65 mm and a concentration of 25 μg/mL. Mean
hydrodynamic radius were 163.5 ± 12.6 and 520.9 ± 41.7 nm for water and saline buffer respectively
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In this context a low blood concentration of Ti cannot
be ruled out. Driven by the quantification method devel-
oped, we then focused on the Ti brain content.
Quantification of titanium dioxide in the brain
IV administration of TiO2 NPs to rats resulted in
trace amount of Ti content in total brain at early end
points (Fig. 3). Ti was significantly detected from
5 min (brain Ti concentration was 261.40 ± 28.86 ng/
g for the treated group vs. 68.25 ± 6.56 ng/g for the
control group, P < 0.001) to 6 h (brain Ti concentra-
tion was 110.00 ± 25.05 ng/g for the treated group vs.
66.75 ± 7.36 ng/g for the control group, P < 0.001)
(Fig. 3a). We found a significant decrease in the cere-
bral tissue Ti concentration after 24 h. Ti content
after 24 h in the treated group did not differ signifi-
cantly from that in the control group. These data are
in agreement with the recent study by Geraets et al.,
who found Ti in rat total brain 24 h after IV admin-
istration of 5 mg/kg doses of different TiO2 NPs
whatever their sizes and crystallinity [18]. Shinohara
et al. also measured traces of Ti in rat total brain 6 h
after IV administration of a 0.95 mg/kg dose of P25
Degussa TiO2 NPs [16]. Fabian et al. did not detect
Fig. 2 Tissue distribution of titanium after IV injection of 1 mg/kg TiO2 NPs in rats. Titanium quantification in liver (a); lungs (b); spleen (c); kidneys
(d); blood cells (e) and plasma (f) of treated (grey) and control (white) animals. Quantification by inductively coupled plasma mass spectrometry (ICP-MS).
Each data point represents the mean ± SD of n = 6 animals. Statistical comparison was performed by two-way ANOVA, *P< 0.05; **P< 0.01; ***P< 0.001
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Ti in the total brain, a result which could be ex-
plained by the sensitivity of the analytical inductively
coupled plasma atomic emission spectroscopy (ICP-
AES) method used.
These observations raise one important question: do
TiO2 NPs cross the BBB and accumulate in the brain
parenchyma or remained located in the brain micro vas-
culature? As a crucial component of the BBB, the BECs
and a fraction corresponding to glial and neural cells re-
ferred to as the parenchyma fraction were separated, as
we described previously [29]. The purity of the resulting
BECs was checked after RNA isolation and real-time
PCR experiments by measuring the expression of cell-
specific marker genes for BECs (CD31 or PECAM) and
for glial cells (glial fibrillary acid protein). The purity of
isolated BECs was 99.58 ± 0.11 % and of the parenchyma
Fig. 3 Titanium quantification in rat brain (a), isolated brain microvasculature endothelial cells (b) and brain parenchyma (c) of treated (grey) and
control (white) animals after IV injection of 1 mg/kg TiO2 NPs and schematic summary of the events and potential effects on the BBB.. Quantification
by inductively coupled plasma mass spectrometry (ICP-MS). Each data point represents the mean ± SD of n = 6 animals. Statistical comparison was
performed by two-way ANOVA, *P < 0.05; **P < 0.01; ***P < 0.001. Consequences and hypothesis of clearance mechanism of TiO2 NPs at the BBB (d).
Transient presence of TiO2 NPs in brain microvasculature endothelial cells leads to overexpression of cytokines and chemokines (IL-1β and IP-10), which
could be linked to the modification of activity or expression of P-gp and BCRP. Integrity of the barrier is not compromised
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fraction 98.52 ± 1.17 %. Analysis of Ti content in these
two separated fractions highlighted rapid internalization
of TiO2 NPs into BECs (at 5 min after IV Ti concentra-
tion in treated group was 6579.33 ± 594.36 ng/g vs
907.16 ± 158.70 ng/g in the control group P < 0.001),
followed by a significant decrease at 2 h (Fig. 3b). With
caution to the background increased in the untreated
animals at 28 days, at 5 min and 2 h after IV a signifi-
cant increase of Ti between controls and treated animals
was found in the parenchyma fraction but correspond to
a very low amount of Ti (Fig. 3c). At 28 days after IV
administration, Ti content in BECs was not different in
the control and treated groups as well as in the paren-
chyma fraction of both same age groups. Notwithstand-
ing the uptake of TiO2 NPs by the BECs and the very
low concentration found in brain parenchyma, our find-
ings suggest that the BBB regulates the uptake and clear-
ance of TiO2 NPs. This is in line with previous in vitro
findings from our laboratory that have demonstrated
rapid internalization of TiO2 NPs by BECs [27] wherein
NPs have been evidenced in vesicles, suggesting that iso-
lated or aggregated NPs can be exported from the cell
via exocytosis. In vivo, two clearance pathways can be
hypothesized: exocytosis back in the blood circulation or
transcytosis across BECs to enter the cerebrospinal fluid
(Fig. 3d). The mechanism of internalization and clear-
ance of Ti from the BECs thus remain to be determined.
BBB physiology modulations
Here we have shown that there is early clearance of
TiO2 NPs at the BBB and significant biopersistence of Ti
in organs (i.e. liver, spleen, etc.) after IV administration
of TiO2 NPs to rats. This raises the question of whether
there is a direct or indirect effect of TiO2 NPs on BBB
physiology in terms of BBB integrity, on regulation of
proteins involved in brain detoxification, such as P-gp
and BCRP, and regulation of neuroinflammation.
BBB integrity
Since alterations in the expression and/or distribution
of tight junction proteins are associated with patho-
physiological conditions, such as neurological disor-
ders (Alzheimer disease, multiple sclerosis, dementia,
epilepsy, etc.) [10, 30–32], we investigated whether the
presence or lack of TiO2 NPs in the BECs after IV admin-
istration to rats would compromises BBB integrity or not.
Occludin and claudins are key proteins in tight junctions
that seal neighboring BECs and limit paracellular diffusion
of substances. The expression of claudin-5 and occludin
mRNA was determined, as well as the partition coefficient
or Kp of atenolol, a known paracellular drug marker [33],
which does not cross the BBB in normal physiological
condition. The marketed increase of atenolol Kp will
reflect the increased in the apparent permeability of aten-
olol attributed to the BBB disruption.
The expression profiles of the genes encoding
claudin-5 and occludin are represented in Fig. 4. In
freshly isolated BECs, their mRNA expression levels
were not significantly different between control and
treated animals at 24 h after IV administration of
TiO2 NPs (Fig. 4a and c). However, notwithstanding
the lack of Ti within the brain, the biopersistence of
Ti in the other organs revealed an increase of
claudin-5 and a slight increase for occludin mRNA
expression (P = 0.057) in the BECs 28 days after IV
administration of TiO2 NPs (Fig. 4b and d). The up-
regulation of tight junction mRNA in BECs correlates
with protein expression evidenced by immunofluores-
cence staining (Figs. 5 and 6). In addition, the brain
to plasma concentration ratio (Kp) of atenolol was
determined. The atenolol Kp between controls and
treated animals remained unchanged (Fig. 7), suggest-
ing lack of BBB breakdown after administration of
1 mg/kg TiO2 NPs in rats. However, higher doses of
TiO2 NPs (10 mg/kg) induced an increase of atenolol
Kp 6 h after IV administration, suggesting compromise
of BBB integrity and testifying for the ability of the integ-
rity probe (Additional file 1). These findings on the conse-
quences of exposing the BBB to TiO2 NPs are in
accordance with observations on the in vitro BBB model
(Additional file 2).
Overall, these data suggest BECs activation at 28 days
and a plausible establishment of a BBB repair mechan-
ism after IV administration of TiO2 NPs (1 mg/kg). This
raises the question of the mediators potentially involved
in these processes.
Regulation of P-gp and BCRP at the BBB
A number of transport and carrier systems are expressed
and polarized on the luminal or abluminal surface of the
BECs. Among these systems, Adenosine triphosphate-
Binding Cassette (ABC) transporters play a critical role
in preventing neurotoxic substances from entering the
brain, and in transporting toxic metabolites out of the
brain. mRNA expressions as well as transport activities
of two major ABC transporters (Abcb1/P-gp and Abcg2/
BCRP) at the BBB were investigated after IV administra-
tion of TiO2 NPs. Data depicted in Fig. 8a and c show
no change in Abcb1 and Abcg2 mRNAs at 24 h in the
rat BECs, while biopersistence of Ti in organs except
brain (28 days) correlated with an increase in Abcb1
mRNAs but not Abcg2 mRNAs expression (Fig. 8b, d),
suggesting differential P-gp and BCRP transporter regu-
lation mechanisms. The regulation of Abcb1 mRNAs has
been also described in the context of oxidative stress,
signaling initiated by Diesel Exhaust Particles for
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example, due to the activation of Nicotinamide Adenine
Dinucleotide Phosphate-oxidase which produces Reactive
Oxygen Species, stimulates Tumor Necrosis Factor - α
(TNF-α) release and activate TNF receptor 1 (TNF-R1). In
turn, TNF-R1 activates the transcription factor Activator
Protein 1 leading to an increase in P-gp expression. Acti-
vation of nuclear factor E2-related factor-2, a sensor of
oxidative stress, also upregulates P-gp expression at the
BBB [34]. To determine whether the increase in mRNA
expressions resulted in changes in protein activity, we
measured the Kp of digoxin and prazosin as examples of
P-gp and BCRP substrates [35–39], respectively. A de-
crease of transporter activity is indicated by his substrate
Kp increase. Functional studies show a rapid down regula-
tion of BCRP activity indicated by a brain increase of
prazosin concentration 6 h after exposure to TiO2
NPs (Kpprazosin = 0.48 ± 0.03 for treated group versus
Kpprazosin = 0.34 ± 0.03 for control group), whereas no
change in transport activity was observed at 24 h, 7
or 28 days after TiO2 NP exposure (Fig. 8e). These
findings pointed out different signaling processes at
the BBB level during early (e.g. direct interaction of
TiO2 NPs with the BBB) and late events (e.g. cytokine
signaling) after IV TiO2 NPs administration to ani-
mals. Such regulation has been evidenced when brain
capillaries was exposed to low levels of Lipopolysac-
charide [34, 40]. We could not correlate the increase
in Abcb1 mRNA expressions 28 days with the P-gp
protein transport activity since brain digoxin concen-
trations were under the quantification limit in both
the controls and the treated group, so P-gp activity
was not measurable. It is worth noticing that this dis-
turbance of P-gp and BCRP expression or activity was
also observed on the in vitro cell based BBB model
after 24 h exposure to TiO2 NPs (data not shown).
Such disturbance of BCRP or P-gp activities could
alter the detoxification function of the BBB. Indeed,
P-gp and BCRP have a very wide variety of substrates
and modulation of their efflux capacities even low
can potentially lead to accumulation of neurotoxics in
the brain parenchyma [41].
Neuroinflammation assessment and relation to
biopersistence of TiO2 NPs in organs
Finally, we were concerned about a potential neuroin-
flammation as such a phenomenon was at stage in our
in vitro cell based BBB model and described in vivo after
intraperitoneal injection of TiO2 NPs [22, 42]. We stud-
ied the influence of the short-term presence of Ti in the
BECs and the impact of biopersistence of Ti in other or-
gans on CNS inflammation, especially at the BBB and in
the brain parenchyma. The presence of Ti in BECs at
early end point depicted in Fig. 3b (significant up to
24 h after IV administration) is correlated with a signifi-
cant increases of interleukin 1β (IL-1β) and chemokine
ligand 1 (CXCL1) (Fig. 9). These increases in addition to
Fig. 4 mRNA expression of tight junction proteins occludin (a, b) and claudin 5 (c, d) in isolated brain microvasculature endothelial cells 24 h or
28 days after IV injection of 1 mg/kg TiO2 NPs in rats. RT-qPCR was performed in duplicate for each single brain microvasculature endothelial cells
preparation. Each data point represents the mean ± SEM of n = 4 animals. Statistical comparison was performed by two tailed Mann-Whitney test,
** P < 0.01. For occludin mRNA expression P = 0.057
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γ inducible protein-10 (IP-10/CXCL10) are maintained
28 days after IV administration, whereas no Ti was de-
tected in BECs or in the brain parenchyma. In the brain
parenchyma, we also noted an increase of interleukin 6
(IL6) expressions at 28 days after IV administration
(Fig. 9). First, the persistent brain inflammation evi-
denced in this study at the brain microvasculature level
28 days after TiO2 NPs exposure raised the question of
Fig. 5 Representative images of immunofluorescence expression of tight junction protein claudin-5 (red) and endothelial cell marker vonWillebrand
factor (vWF, green) in the cerebral microvasculature of (a) control rats, or tissues collected from rats treated with 1 mg/kg TiO2 (IV) at (b) 5 min; (c) 6 h;
(d) 24 h or (e) 28 days post-treatment. Yellow fluorescence indicates overlay (co-localization) of claudin-5 and vWF. Arrows indicate areas of increased
yellow fluorescence. Graph in (f) shows analysis of relative fluorescence of overlay images ± SD. *P < 0.050 compared to controls
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potential brain dysfunction. Indeed, a link between per-
sistent neuro-inflammation and brain pathologies as
already been established [43]. Second, modifications of
P-gp and structural tight junction protein mRNA ex-
pressions come with modulation of cytokines and
chemokines 28 days after TiO2 NPs administration to
rats. This is not correlated with measurable Ti brain and
plasma content. In this context, an indirect mechanism
of interactions between NPs and BECs could be sug-
gested. It is likely that soluble mediators interacts with
Fig. 6 2Representative images of immunofluorescence expression of tight junction protein occludin (red) and endothelial cell marker vonWillenbrand
factor (vWF, green) in the cerebral microvasculature of (a) control rats, or tissues collected from rats treated with 1 mg/kg TiO2 (IV) at (b) 5 min; (c) 6 h;
(d) 24 h; or (e) 28 days post-treatment. Yellow fluorescence indicates overlay (co-localization) of occludin and vWF. Arrows indicate areas of increased
yellow fluorescence. Graph in (f) shows analysis of relative fluorescence of overlay images ± SD. * P < 0.050 compared to controls
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their BBB targets and elicit BECs activation and neuro-
vascular inflammation. For example, pro-inflammatory
mediators such as TNFα distributed through the sys-
temic circulation affect ABC transporter expression and
activity [44, 45]. We thus suggest that 28 days after
exposure, circulating cytokines and chemokines released
probably by organs containing high amounts of Ti in-
duce activation of BECs and initiate the release of IL-1β,
IP-10 and CXCL1, which act in a paracrine way to acti-
vate astrocytes/microglia cells in the brain parenchyma.
Immunofluorescence staining revealed an increase of IL-
1β in the rostral and caudal diencephalon (Fig. 10).
Because of its massive and biopersistence of Ti, liver
could be a key organ for induction of oxidative stress,
lipid composition modifications, and immune response
as reported elsewhere [25, 46–48]. Mediators such as
cytokines, chemokines and lipids circulating in the blood
may be responsible indirectly for BBB deregulation at
late end points. Transposition of the effect evidenced at
the BBB on other endothelial cells by blood circulating
factors could not be excluded.
Circulating serum factors from rats treated with TiO2 NPs
induce an inflammatory response in a cell-based BBB
model
To demonstrate whether circulating cytokines/mediators
that may be released by organs bioaccumulating Ti can
lead to neurovascular inflammation and BBB physiology
alterations, we performed in vitro studies on the primary
rat cell-based BBB model described previously [26]. The
model was exposed to diluted sera from untreated and
treated animals collected 28 days after exposure to TiO2
NPs. Exposure of the apical compartment mimics blood-
borne exposure. After 24 h of exposure to serum, the
integrity of the BECs monolayer was checked and BECs
and glial cells were recovered for mRNA profiling.
After 24 h of exposure, the integrity of the BECs mono-
layer remained intact in the control group as well as in the
treated group (Fig. 11f), thus confirming the maintenance
of BBB integrity observed 28 days after exposure in vivo
(apparent permeability (Papp) for Lucifer Yellow (LY) was
2.08 ± 0.99 cm/s for controls vs 2.17 ± 0.77 cm/s for the
treated group). In BECs, we noted a tendency of increase
for occludin mRNA expression (P = 0.057), which is in
accordance with in vivo observations. The mRNA expres-
sions of IL6, CXCL1 and glial fibrillary acid protein
(GFAP) in astrocytes were upregulated. These inflam-
matory markers are key proteins for communication
between glial and BECs [49–54]. This in vitro mRNA
upregulation in glial cells of the BBB model suggests
that the mediators are present 28 days after exposure
in the serum of treated rats and allows to consolidate
our hypothesis of circulating mediators.
Conclusions
The major findings of our study are depicted in Fig. 12 and
Fig. 3d. They show a Ti burden in the liver, spleen and
lungs up to 356 days after IV administration of TiO2 NPs
to rats, with very low clearance rate observed until one year
after administration. Additionally, we describe for the first
time the in vivo uptake and clearance by BECs of TiO2 NPs
after exposure. Furthermore, this is the first study reporting
the link between deregulation of BBB physiology and the
presence of TiO2 NPs in distal organs. Upregulation of tight
junction proteins, modulation of P-gp mRNA expression
and persistent brain inflammation markers such as
IL-1β, IP-10 and CXCL1 were highlighted. Thus, re-
gardless of where the peripheral signal originates
from, our findings raise the question of circulating
biomarkers potentially released by organs accumulating Ti
to promote dysregulation of BBB physiology and neuroin-
flammation. Substantial research remains to be done to
identify such peripheral biomarkers. Our findings point
out for the first time that TiO2 NPs can exert indirect ef-
fect on the CNS that seems dependent on the circulation.
Materials and methods
Chemicals
Human serum, bovine serum albumin (BSA), N-alpha-
tosyl-L-lysinyl-chloromethylketone (TLCK) and Lucifer
yellow (LY), Digoxin, Prazosin, Atenolol and Atenolol-
d7 were from Sigma Aldrich (Saint-Quentin Fallavier,
France). Collagenase/dispase and DNAse I were from
Roche Applied Science (Basel, Switzerland). Digoxien-d3
was from Artmolecule (Poitier, France).
All chemicals used for ICP-MS were of analytical
grade. Nitric acid was used to prepare 0.2 % HNO3 (v/v)
with ultrapure water. All single element stock solutions
Fig. 7 BBB integrity assessment. The integrity was estimated by
the ratio between atenolol concentrations in brain and plasma
(partition coefficient or Kp) at 6 h, 24 h, 7 days and 28 days after IV
administration. Each data point represents the mean ± SD of n = 4
rats. Statistical comparison was performed by two-way ANOVA
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(1000 mg/L) were delivered by SCP Science and certi-
fied for purity and concentration. From these stock
solutions, a mixed working standard solution with a
concentration of 10 mg/L for each element was pre-
pared by putting 1 mL of each stock solution in a
100 mL measuring flask, adding 5 mL of purified
Fig. 8 mRNA expression of transporters Abcb1 (P-gp) and Abcg2 (BCRP) transporters in isolated brain microvasculature endothelial cells and BCRP
activity assessment at the BBB after IV injection of 1 mg/kg TiO2 NPs in rats. mRNA transcription profiles for Abcb1 (a; b) and Abcg2 (c; d) were
performed by RT-qPCR in isolated rat brain microvasculature endothelial cells of control and treated animals. Each data point represents the mean ±
SEM of n = 4 animals and RT-qPCR was performed in duplicate for each single preparation of brain microvasculature endothelial cells. Statistical
comparison was performed by two tailed Mann-Whitney test, *P < 0.05. BCRP activity (e) was estimated by the ratio between prazosin concentrations
in brain and plasma (partition coefficient or Kp). Each data point represents the mean ± SD of n = 4 rats. Statistical comparison was performed by
two-way ANOVA, *P < 0.05
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Fig. 9 (See legend on next page.)
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HNO3 and diluting to 100 mL with ultrapure water
(MilliQ, Millipore, Germany).
TiO2 nanoparticles
TiO2 P25 NPs (Aeroxide® P25, 75 % anatase 25 % rutile,
Evonik®) were from Sigma Aldrich (Saint-Quentin Falla-
vier, France). For in vivo experiments, TiO2 NPs were
suspended in sterile physiological salt solution at a stock
concentration of 1 mg/mL. No other treatment was per-
formed. A thorough characterization of NPs was con-
ducted through a panel of complementary techniques.
NPs were imaged by Transmission Electron Microscopy
(TEM) with a JEOL 1400 instrument (JEOL, Tokyo,
Japan) operating at 80 keV (Imagif platform, Gif-sur-
Yvette) and Scanning Electron Microscopy (SEM) (Carl
Zeiss, Ultra 55) equipped with an Energy Dispersive X-
ray spectrometer (EDX) allowing elemental analysis. For
both TEM and SEM analyses, samples were prepared as
follows: 3 μL droplet of the dispersion was cast on for-
mvar/ carbon-coated copper grids for 5 min. The
Brunauer-Emmett-Teller (BET) method (Micromeritics
FlowsorbII 2300) was applied to determine the specific
surface area (SSA) of the nanopowder and diameter was
calculated from the SSA value, as D = 6 000/(ρ.SSA),
where D is BET diameter (nm), and ρ = 3.9 g.cm−3 is the
density of anatase TiO2. The crystalline phases were
measured by X-Ray Diffraction (XRD) with a Siemens
D5000 instrument using the Cu-Kα radiation and using
the Match software (crystal impact). Hydrodynamic
diameter was measured by Dynamic Light Scattering
(DLS) using a ZetaSizer ZEN3600 (Malvern, Herenberg,
Germany) equipped with a 633 nm laser.
Animals and intravenous TiO2 NPs administration
protocol
Male Fisher F344 rats (from Charles River Laboratories,
France), 8 weeks old and weight 180–250 g, were housed
in standard environmental conditions (room humidity and
temperature controlled 19 °C–23 °C; room under a 12 :
12 h light dark cycle) and maintained with free access to
water and standard laboratory diet. The control animals
were injected intravenously via the tail vein with 1 mL/kg
of sterile saline buffer and the treated animals were
injected with TiO2 NPs suspension at the dose of 1 mg/kg.
TiO2 NPs suspension was vortex for 5 min before admin-
istration. No other dispersion protocol was used to avoid
false positive results that would be due to inappropriate
handling of the dispersion protocol of NPs.
30 min, 1 h, 2 h, 6 h, 24 h, 7 days, 28 days, 90 days or
356 days after IV injection, animals were anesthetized with
isoflurane and euthanized. Additional time points at
5 min and 15 min was set up for brain and blood collec-
tion. Blood, liver, brain, spleen, kidneys and lungs were
collected and stored at −80 °C until assayed. All proce-
dures were approved by the CEA Institute’s Animal Care
and Use Committee and conform to the Guide for the
Care and Use of Laboratory Animals published by the
European community’s council (directives 86/609/EEC,
November 24, 1986), and the French directives concerning
the use of laboratory animals (February 2013).
Sample Preparation and Ti analysis by ICP-MS
Tissues from 6 controls and 6 treated rats were used for
biodistribution studies. Tissues were thawed and about
0.1–0.3 g of each tissue was weighed, digested and ana-
lyzed for Ti content. Each sample was added to a 55 mL
microwave digestion vessel along with 8 mL of nitric
acid and 2 mL of hydrofluoric acid and digested using a
Microwave Assisted Reaction System (MARS) Express
instrument. The microwave digestion program was
15 min; 150 °C; 1200 W then 15 min; 180 °C; 1200 W
followed by 20 min cooling. After cooling, the sample
was rinsed 3 times using approximately 20 mL of 2 %
nitric acid solution in a polytetrafluoroethylene (PTFE
or Teflon) beaker. 2 mL of hydrogen peroxide was added
to each beaker to digest any remaining organic matter.
The beaker was then heated on a hot plate at 180 °C until
between 0.1 and 0.5 mL of solution remained. The beakers
were removed from the hot plate, allowed to cool and
rinsed 3 times with 2 % nitric acid solution into a 25 mL
volumetric flask before being stored for analysis. Samples
were refrigerated at −20 °C while not in use.
This digestion method was evaluated for the recovery
of a known amount of TiO2 and the ability to digest or-
ganic material sufficiently for analysis. The method was
applied to a number of blank samples, containing only
the reagents and no sample, in order to measure the
amount of Ti contamination.
Analysis of Ti with ICP-MS
Ti standard solutions for ICP-MS calibration were pre-
pared at concentrations of 2, 4, 8, 10, 30, 50 and 100 ng/
(See figure on previous page.)
Fig. 9 mRNA expression of cytokines and chemokines in isolated brain microvasculature endothelial cells and parenchyma fraction after IV
injection of 1 mg/kg TiO2 NPs in rats. mRNA transcription profiles for IL-1β, IP-10 and CXCL1 in isolated rat brain microvasculature endothelial cells
and IL6 in parenchyma fractions of control and treated animals performed by RT-qPCR at 24 h (a) and 28 days (b) after IV injection. Each data
point represents the mean ± SEM of n = 4 animals and RT-qPCR were performed in duplicate for each single preparation of brain microvasculature
endothelial cells. Statistical comparison was performed by one tailed Mann Whitney test, *P < 0.05; ** P < 0.01
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L, by diluting a 1 g/L Ti standard stock solution
(1.70363.0100, SCP Science) with 2 % v/v HNO3 and
0.01 % v/v Triton X-100. An internal standard solution,
containing 25 μg/L of Ge was prepared by diluting a
1000 mg/L internal standard stock solution (1.70320.0100,
Merck) with 2 % v/v HNO3. The internal standard (25 μg/
Fig. 10 Representative images of immunofluorescence expression of IL-1β in the cerebral parenchyma of (a) control rats, or tissues collected from rats
treated with 1 mg/kg TiO2 (IV) at (b) 5 min; (c) 6 h; (d) 24 h; or (e) 28 days post-treatment. Arrows indicate sagittal suture (coronal cut, sections cut and
analyzed between rostral and caudal diencephalon). Graph in (f) shows analysis of relative fluorescence of overlay images ± SD. *P < 0.050 compared
to controls
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Fig. 11 Impact of exposure to sera from treated animals on the in vitro BBB model. (a) is a schematic view of the model architecture. BECs were
grown on a semipermeable membrane whereas glial cells lay on the well bottom. mRNA expressions were quantified by RT-qPCR after 24 h exposure
to sera from control and treated rats. For glial cells, expressionsof cytokines and chemokines (IL6 (b), CXCL1 (c)) and of GFAP (d) are presented. For
BECs, tight junction protein occludin (Ocln (e)) is reported and integrity of the BECs monolayer was checked in terms of apparent permeability to
Lucifer yellow (f). Sera diluted in culture medium were applied to the BECs compartment for 24 h. Each data point represents the mean ± SEM of n = 4
samples, each sample representing the mRNA pool from 6 wells. RT-qPCR was performed in duplicate for each single sample. Statistical comparison
was performed by one tailed Mann Whitney test, * P < 0.05 for IL-6, CXCL1 and GFAP mRNA expressions. Statistical comparison was performed by two
tailed Mann Whitney test for Ocln mRNA expression (P = 0,057)
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L Ge) was added in all samples and standards. Ti analysis
of acidified samples was carried out using a Varian 820-
MS. Samples in 2 % v/v HNO3 were directly analyzed with
the Varian-820-MS for Ti determination.
BBB permeability and P-Glycoprotein and BCRP transport
activity measurement
Four hours before sacrifice, 4 control and 4 treated rats
were subcutaneously implanted with mini-osmotic pumps
(Alzet model 2001D; DURECT Corp., Cupertino, Califor-
nia). Pumps were filled with atenolol, digoxin and prazosin
dissolved in PEG200/DMSO (50/50) to deliver at 0.25 mg/
kg/h, 0.5 mg/kg/h or 0.25 mg/kg/h rates, respectively. The
relevance of distribution study of atenolol, digoxin and
prazosin in plasma and brain for BBB integrity and trans-
port function assessment was previously demonstrated
[26, 29]. 6 h, 24 h, 7 d or 28 d after IV injection, animals
were anesthetized with isoflurane and euthanized. Plasma
samples and brain were collected and weighed immedi-
ately after death. The administered substrates were quan-
tified in the two compartments using mass spectrometry
coupled with liquid chromatography (LC/MS). BBB integ-
rity was estimated by the ratio of atenolol brain to plasma
concentration (Cbrain and Cplasma, respectively). This ratio
is described by the partition coefficient (Kp).
Kp ¼ Cbrain
Cplasma
The P-gp and BCRP transport activities were esti-
mated by means of the digoxin and prazosin Kp,
respectively.
Fig. 12 Schematic summary of the events and potential effects on BBB physiology in the case of bioaccumulation of TiO2 NPs in organs. Exposure to
circulating mediators that maybe originate from organs bioaccumulating titanium leads to neurovascular inflammation. Overexpression of IL-1β, CXCL1
and IP-10 may contribute to modification of brain endothelial cell physiology in terms of expression of tight junction proteins (occludin and claudin-5)
and ABC transporters (P-gp and BCRP). In parallel, key inflammatory markers for glial and endothelial cells interactions were upregulated
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LC/MS assay for digoxin, prazosin and atenolol
quantification
Brains were mixed in ultrapure water (2 mL/g of tissue)
using an Ultraturrax T65 system (IKA-Werke, Staufen,
Germany). Extract suspensions (400 μL) were submitted
to protein precipitation with 1 mL of methanol previ-
ously spiked with internal standard (digoxin-d3 and
atenolol-d7 4 μg/mL). After centrifugation (20000 g;
15 min; 4 °C) the supernatant was dried under nitrogen
at 40 °C. The dried extracts were resuspended in 1 mL
0.75 M NH4OH / methanol (80:20 v/v). Plasma (150 μL)
was diluted with 150 μL of 0.75 M NH4OH / methanol
(80:20 v/v) previously spiked with internal standard. Both
brain and plasma extracts were submitted to solid-liquid
extraction on isolute SLE+ columns 1 or 6 mL (Biotage).
The two eluates (3 mL of dichloromethane/isopropanol
(70:30 v/v) then 3 mL of dichloromethane/isopropanol
(70:30 v/v) + 0.2 % formic acid) were pooled and evapo-
rated to dryness. The dry extracts were resuspend in
200 μL of 5 mM ammonium acetate/methanol (95:5 v/
v). Chromatography was performed using a Shimadzu
HPLC system LC 20 AD on a Kinetex C18 column (Phe-
nomenex). The total run time was 5 min and the flow
rate was 0.4 mL/min. Analyte (20 μL) was injected onto
the column placed in an oven at 40 °C.
Detection was done by tandem mass spectrometry
(Finnigan TSQ Quantum Discovery with Xcalibur and
LC Quan softwares, Thermo) in positive electrospray
mode. Tuning parameters were: capillary voltage 3 kV,
source temperature 200 °C. The multiple reaction moni-
toring transitions for analytes were as follows: m/z di-
goxin 798.5 > 651.4, m/z prazosin 384.19 > 247.14, m/z
atenolol 267.18 > 145.1. Analytes were quantified by
means of calibration curves using digoxin-d3 or
atenolol-d7 as internal standard. For plasma and brain
extract assay, calibration ranges were from 1.0 to
200 ng/mL.
Isolation of brain microvasculature endothelial cells
Rat brain capillaries were isolated as described previ-
ously [26, 55]. 6 rats from three relevant time groups
(5 min; 2 h and 28 days) were used. Brains were ex-
tracted and stored in Hanks balanced salt solution
(HBSS) supplemented with 1 % (v/v) PSN on ice. The re-
mainder of the isolation took place under aseptic condi-
tions. The brains were cut sagittally into two halves and
the cerebral cortices emptied of white matter. The men-
inges and the associated vessels were cleaned off by roll-
ing on Whatman 3 mm chromatography paper. The
homogenized tissue was pelleted by centrifugation at
1500 rpm for 5 min. The pellet containing the microves-
sels was digested in HBSS-1 % PSN solution, 1 mg/mL
collagenase/dispase, 10 U/μL DNase-I, and 1 μg/mL
TLCK for 1 h at 37 °C. Digested tissue was then pelleted
by centrifugation at 1500 rpm for 5 min at 4 °C. To re-
move myelin, the pellet was resuspended in 20 % (w/v)
BSA in HBSS-1 % PSN solution and centrifuged at
2800 rpm for 30 min. The resulting floating white mat-
ter corresponding to the brain parenchyma fraction and
centrifugation medium were removed carefully. The
microvessel pellets were washed then frozen at −80 °C.
The remaining parenchyma fraction was resuspended in
centrifugation medium then half-dissolved in HBSS-1 %
PSN solution and pelleted by centrifugation at 1500 rpm
for 15 min. The brain parenchyma pellet was then
washed several times before being frozen at −80 °C.
Cell culture
Rat primary BECs and glial cells were isolated and cul-
tured as previously described [26]. Briefly, for BECs,
brain tissues were digested enzymatically (1 g/L collage-
nase/dispase, 20 U/mL DNAse I, 0.147 mg/L TCLK in
HBSS, 1 h at 37 °C). A 20 % BSA gradient was used for
isolation of capillaries. After a second enzymatic diges-
tion, cells were plated in 75 cm2 coated culture flasks in
EBM medium completed by the EGM-2 MV Single-
Quots kit (Lonza, Basel, Switzerland). Cultures were
maintained at 37 °C in a humidified 5 % CO2 atmos-
phere for 5–6 days before being trypsinized and frozen.
BBB cell-based model
For BBB modeling, glial cells were seeded at a density of
5700 cells/cm2 on transwell plates in a glial-specific
basal medium as previously reported [26]. BECs were
plated on the upper side of a coated polyester transwell
membrane (pore size 0.4 mm, Costar, Dutscher sa,
Brumath, France) at a density of 71400 cells/cm2 in a
BEC-specific medium. Microplates were then incubated
at 37 °C in a humidified 5 % CO2 atmosphere for 5 to
7 days before treatment. Upper and lower chambers will
be referred to as apical and basal compartments, re-
spectively, throughout this manuscript. 4 sera from con-
trols and 4 sera from treated animals were tested. Each
collected serum from controls and treated animals were
diluted at 1/16 in the BEC medium. BECs were exposed
to diluted rat serum in the apical compartment for 24 h.
Transport experiments were performed in six wells for
each serum.
Transport experiments
After exposure to sera, exposure medium were removed
then transwells with BECs were transferred to new
plates. 0.5 and 1.5 mL of transfer buffer (150 mM NaCl,
5.2 mM KCl, 2.2 mM CaCl2, 0.2 mM MgCl2, 6 mM
NaHCO3, 2.8 mM glucose and 5 mM Hepes) was added
to the apical and basolateral compartments or donor
and acceptor chambers, respectively. Lucifer yellow (LY)
was added to the donor chamber to a final concentration
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of 0.1 mM and, after 30 min, aliquots from acceptor
and donor chambers were collected for determination
of tracer concentration by fluorescence counting. The
apparent permeability (Papp) value for LY was calcu-
lated as follows:
Papp ¼ dQ ¼ dT  A  C0
where dQ/dT is the amount of LY transported per
time-point, A is the membrane surface area and C0 the
initial donor concentration. The mass balance (R) was
calculated as:
R %ð Þ ¼ 100  A þ Dð Þ=D0½ 
where A and D are the amounts of LY in the acceptor
and donor chambers and D0 is the amount introduced
at t: 0. Mass balances of LY were between 80 and 120 %.
As LY permeability values on the order of 10−6 cm/s
were obtained previously in various in vitro BBB models
[33, 56–58] , we considered that beyond 5.10−6 cm/s the
monolayer is disrupted.
Transcription profiling
RNA was isolated from rat BECs, brain parenchyma
fraction or cells isolated from the BBB in vitro model
using the RNeasy plus universal tissue minikit or the
RNeasy Mini kit, respectively (Qiagen, France), accord-
ing to the manufacturer’s instructions. The concentra-
tion and purity of the RNA samples were assessed
spectrophotometrically at 260 and 280 nm using the
NanoDrop ND-1000 instrument (NanoDrop Technolo-
gies, Wilmington, DE, USA). The A260/280 ratio ranged
between 1.8 and 2.
A sample of 0.5 μg of total RNA was converted to
cDNA with random primers in a total of 10 μL using an
RT2 first stand kit (Qiagen, France). The cDNA was
diluted with DNA/RNAse-free distilled water to a vol-
ume of 110 μL.
The quantitative expression of various cytokines, che-
mokines, transporters and structural proteins was deter-
mined using 0.4 μM cDNA for each primer set in the
RT2 Pathway Focus profiler array from Qiagen. The RT2
Profiler array consists of a previously validated qRT-PCR
primer set (1 μL) for relevant cytokines, chemokines: Il-
1β, CXCL1 and IP-10; tight junction proteins: Cldn5 and
Ocln; ABC transporters: Abcb1 and Abcg2 and house-
keeping genes (Hprt, GAPDH). Thermocycling was car-
ried out in a CFX96 real-time PCR detection system
(Bio-Rad) using SYBR green fluorescence detection. The
final reaction mixture contained 2 μL of diluted cDNA,
1 μL of one of the specific primer, 12.5 μL of distilled
water and 9.5 μL of SYBR green master mix. The spe-
cific amplification conditions were 2 min at 50 °C,
10 min at 95 °C followed by 40 amplification cycles at
95 °C for 0.5 min, and 60 °C for 1 min to reinitialize the
cycle again. The specificity of each reaction was also
assessed by melting curve analysis to ensure the pres-
ence of only one product. Relative gene expression
values were calculated as 2−ΔCT, where ΔCT is the differ-
ence between the amplification curve (CT) values for
genes of interest and housekeeping genes (hypoxanthine
guanine phosphoryltransferase or Hprt; glyceraldehyde
phosphodehydrogenase or GAPDH). If the CT was
higher than 35, we considered the expression level too
low to be applicable.
Immunofluorescence
Brain sections embedded in OCT and cut on a cryostat
(10 μm) were prepared for either occludin or claudin-5,
and von Willebrand factor (vWF) double immunofluor-
escence, or IL-1β. Brain sections were air-dried for
30 min and fixed in ice-cold acetone for 30 min and
then rinsed in PBS. Sections were then incubated with
3 % BSA for 60 min at RT, rinsed in PBS, and incubated
with 150 μL per section of the appropriate primary anti-
body (occludin: 1:1000, Abcam, Cambridge, MA; clauin-
5: 1:100, Invitrogen/Life Technologies, Carlbad, CA) and
an FITC-tagged vWF (1:1000 dilution, Abcam) or IL-1β
(1:1000, Abcam) alone; diluted in wash buffer [1 part
5 % blocking solution (0.5 mL normal rabbit serum in
10 mL 3 %w/v bovine serum albumin) and 4 parts
phosphate-buffered saline (PBS)] for 1 h at room
temperature (RT) and then rinsed 3 times with PBS. The
slides were incubated in 150 μL per section of the ap-
propriate secondary antibody with either Alexa Fluor
555 or Alexa Fluor 546 (1:1000 dilution, Vector Labora-
tories, Biovalley, Marne la Vallée, France) in the dark for
1 h at RT. Slides were rinsed 3 times in PBS and subse-
quently incubated with Hoechst nuclear stain (1 μL/mL;
150 μL/section) for one minute, rinsed again then cover-
slipped with Aqueous Gel Mount (TBS, Fisher Scientific,
Waltham, MA). Slides were imaged by fluorescence
microscopy at 10x and 40x, using the appropriate excita-
tion/emission filters, digitally recorded, and analyzed by
image densitometry using Image J software (NIH). A
minimum of 3 locations on each section (2 sections per
slide), 3 slides and n = 3 per group were processed/ana-
lyzed. Only vessels >50 μm were used for analysis.
Statistical Analysis
Analyses were performed using the Prism 5.1 program
(GraphPad Software, Inc, San Diego CA). Statistical
comparisons conducted herein were accomplished using
variance analysis (two-way ANOVA) two determinants
being time and treatment for organs Ti distribution
followed by the Bonferroni post test. mRNA expression
of cytokines and chemokines were analyzed using one
tailed Mann-Whitney test and two tailed Man Whitney
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test for other mRNA expressions (tight junctions pro-
teins and transporters). Immunofluorescence end points
were analyzed using one-way ANOVA between treat-
ment groups followed by the Holm-Sidak post hoc test
(SigmaPlot SyStat Software Inc, San Joes, CA) and data
were expressed as mean ± SD. Changes were considered
statistically significant at P < 0.05.
Additional files
Additional file 1: BBB integrity assessment after IV injection of
10 mg/kg TiO2 NPs in rats. BBB integrity was estimated by the ratio
between atenolol concentrations in brain and plasma (partition coefficient
or Kp). Each data point represents the mean ± SD of n = 8 rats. Statistical
comparison was performed by two tailed Mann-Whitney test, * P < 0.05.
(TIFF 4945 kb)
Additional file 2: Effect of 24 h TiO2NPs exposure on BEC
epithelium integrity. TiO2 NPs concentrations from 0 to 100 μg/mL
were applied to the apical pole of the in vitro BBB model for 24 h. Data
are apparent permeability coefficient of sucrose. Each data point represents
the mean ± SD of at least 2 experiments. The horizontal dotted line
represents the usual limit value of 8.3 10-6 cm.s−1 beyond which the BEC
monolayer is considered to be disrupted. The blue zone represents sucrose
apparent permeability coefficient for the controls (Mean ± SD). (TIFF 61 kb)
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